An­oth­er batch of in­sulin re­called by Vi­a­tris due to a la­bel­ing is­sue

In Jan­u­ary, Vi­a­tris — the com­bi­na­tion of My­lan Phar­ma­ceu­ti­cals and Pfiz­er’s Up­john — was forced to re­call a batch of its Sem­glee in­sulin pens af­ter they were re­leased with­out la­bels, the FDA said.

Ear­li­er this week, the com­pa­ny an­nounced a re­call of an­oth­er batch of in­sulin glargine for in­jec­tion, this time in car­tridge form, for the same la­bel is­sue.

This new batch of 10 mL vials, with an ex­pi­ra­tion date of Au­gust 2023, was made by Bio­con and dis­trib­uted by My­lan. The pre­vi­ous fault fea­tured a sin­gle batch of non-in­ter­change­able in­jec­tion, 100 units/ml, 3mL pack­aged in car­tons of five pens with an Au­gust 2022 ex­pi­ra­tion date. The batch num­ber was BF20003118, made by Bio­con, and dis­trib­uted by My­lan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER